Yamaguchi, Ayane
Kawaguchi, Kosuke http://orcid.org/0000-0002-3161-7981
Kawanishi, Kana
Maeshima, Yurina
Nakakura, Akiyoshi
Kataoka, Tatsuki R.
Takahara, Sachiko
Nakagawa, Shunsaku
Yonezawa, Atsushi
Takada, Masahiro
Kawashima, Masahiro
Kawaguchi-Sakita, Nobuko
Kotake, Takeshi
Suzuki, Eiji
Shimizu, Hanako
Torii, Masae
Morita, Satoshi
Ishiguro, Hiroshi
Toi, Masakazu
Funding for this research was provided by:
Japan Society for the Promotion of Science (21K15530, 22K15605)
Article History
Received: 17 June 2023
Accepted: 12 October 2023
First Online: 21 December 2023
Declarations
:
: KK received grants from TERUMO, Astellas, Eli Lilly, Kyoto Breast Cancer Research Network; consulting fees from Becton Dickinson Japan; and honoraria from Eisai, Chugai, and Takeda; MT received a grant from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, JBCRG Assoc., Eisai, Eli Lilly, Daiichi Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI Technology, Luxonus, Shionogi, and GL Science and honoraria from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi Sankyo, AstraZeneca, Eli Lilly, MSD, Exact Science, Novartis, Konica Minolta, Shimadzu, Yakult, and Nippon Kayaku; is a member of Advisory Board for Kyowa-Kirin, Daiichi Sankyo, Eli Lilly, Konica Minolta, BMS, Athenex Oncology, Bertis, Terumo, and Kansai Medical Net; Board of Directors of JBCRG Assoc., KBCRN, and OOTR; is an Associate Editor of the British Journal of Cancer, Scientific Reports, Breast Cancer Research and Treatment, Cancer Science, Frontiers in Women’s Cancer, Asian Journal of Surgery, and Asian Journal of Breast Surgery; and Deputy Editor of International Journal of Oncology. HI received a grant from Eisai Co., Ltd., Daiichi Sankyo Co., Ltd, AstraZeneca plc, MSD K.K., Sanofi S.A., Daiichi Sankyo Co., Ltd., Taiho, Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., LabCorp Japan, G.K., Kyowa Kirin Co., Ltd., Nippon Kayaku Co., Ltd., Sawai Pharmaceutical Co., Ltd., Covance Japan Co., Ltd., and Maruho and honoraria from Eisai Co., Ltd. Chugai Pharmaceutical Co., Ltd., Pfizer Inc., Kyowa Kirin Co., Ltd., EP-Force Co., Ltd., and JMS. The other authors have no conflicts of interest to declare. MK received a grant from NIPPON KAYAKU CO., LTD., Kyowa Kirin Co., Ltd., Guardant Health AMEA, GL Sciences Inc. and honoraria from Pfizer Japan Inc., CHUGAI PHARMACEUTICAL CO., LTD. MT received a grant from AstraZeneca, Daiichi Sankyo, Kyoto Breast Cancer Research Network, ABCSG, Yakult, Medbis, and Japan Breast Cancer Research Group and honoraria from Chugai, AstraZeneca, Daiichi Sankyo, Lilly, Eisai, Nippon Kayaku, Pfizer, and Mitaka Khoki.
: This retrospective observational study was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine. The approval numbers are G424 and R2135.
: This is a retrospective, non-invasive study. Opt-out with Ethics Committee approval provided the opportunity to refuse to participate in the study.
: Not applicable.